eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
schneider said that he is hoping to conduct a subsequent study of 15 to 20 pregnancies and that he is encouraged by these results.
.
.
.
.#1 in news, talk, and sports in los angeles and orange county
.
.
.
.
.#1 in news, talk, and sports in los angeles and orange county
.
.